SSY GROUP (02005): Mabalocevir has been approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed formulations.
Shi Si Pharmaceutical Group (02005) announced that their marbavir has been approved by the China National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed preparations. This makes it the third domestic company to receive approval.
SSY GROUP (02005) announced that its drug Mabalonavir has been approved by the China National Medical Products Administration to be registered as an active pharmaceutical ingredient for use in marketed formulations, making it the third domestic company to receive approval.
Mabalonavir is mainly used to treat Influenza A and B viruses.
Related Articles
TASTEGOURMET GP (08371) plans to open a new Kin Long Teppanyaki restaurant in Hong Kong.
ANTENGENE-B (06996) received a $60 million upfront payment from UCB for ATG-201.
CGN NEW ENERGY (01811) completed a total electricity generation of 1,331.5 GWh in June, representing a decrease of 5.1% compared to the same period last year.
TASTEGOURMET GP (08371) plans to open a new Kin Long Teppanyaki restaurant in Hong Kong.
ANTENGENE-B (06996) received a $60 million upfront payment from UCB for ATG-201.
CGN NEW ENERGY (01811) completed a total electricity generation of 1,331.5 GWh in June, representing a decrease of 5.1% compared to the same period last year.
RECOMMEND
